Antibe Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Dan Legault

Chief executive officer

CA$784.9k

Total compensation

CEO salary percentage65.6%
CEO tenure15yrs
CEO ownership2.1%
Management average tenure4.1yrs
Board average tenureno data

Recent management updates

Recent updates

Is Antibe Therapeutics (TSE:ATE) In A Good Position To Invest In Growth?

Dec 15
Is Antibe Therapeutics (TSE:ATE) In A Good Position To Invest In Growth?

We Think Antibe Therapeutics (TSE:ATE) Needs To Drive Business Growth Carefully

Mar 20
We Think Antibe Therapeutics (TSE:ATE) Needs To Drive Business Growth Carefully

Antibe Therapeutics (TSE:ATE) Is In A Strong Position To Grow Its Business

Oct 16
Antibe Therapeutics (TSE:ATE) Is In A Strong Position To Grow Its Business

Antibe Therapeutics Inc.'s (TSE:ATE) Profit Outlook

Feb 11
Antibe Therapeutics Inc.'s (TSE:ATE) Profit Outlook

We're Keeping An Eye On Antibe Therapeutics' (TSE:ATE) Cash Burn Rate

Jan 07
We're Keeping An Eye On Antibe Therapeutics' (TSE:ATE) Cash Burn Rate

Auditors Are Concerned About Antibe Therapeutics (CVE:ATE)

Jul 31
Auditors Are Concerned About Antibe Therapeutics (CVE:ATE)

Need To Know: The Consensus Just Cut Its Antibe Therapeutics Inc. (CVE:ATE) Estimates For 2021

Jul 29
Need To Know: The Consensus Just Cut Its Antibe Therapeutics Inc. (CVE:ATE) Estimates For 2021

CEO Compensation Analysis

How has Dan Legault's remuneration changed compared to Antibe Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-CA$18m

Sep 30 2023n/an/a

-CA$18m

Jun 30 2023n/an/a

-CA$19m

Mar 31 2023CA$785kCA$515k

-CA$19m

Dec 31 2022n/an/a

-CA$21m

Sep 30 2022n/an/a

-CA$22m

Jun 30 2022n/an/a

-CA$24m

Mar 31 2022CA$715kCA$443k

-CA$25m

Dec 31 2021n/an/a

-CA$26m

Sep 30 2021n/an/a

-CA$26m

Jun 30 2021n/an/a

-CA$25m

Mar 31 2021CA$3mCA$357k

-CA$24m

Dec 31 2020n/an/a

-CA$25m

Sep 30 2020n/an/a

-CA$23m

Jun 30 2020n/an/a

-CA$21m

Mar 31 2020CA$1mCA$311k

-CA$19m

Dec 31 2019n/an/a

-CA$17m

Sep 30 2019n/an/a

-CA$16m

Jun 30 2019n/an/a

-CA$13m

Mar 31 2019CA$2mCA$311k

-CA$13m

Dec 31 2018n/an/a

-CA$11m

Sep 30 2018n/an/a

-CA$9m

Jun 30 2018n/an/a

-CA$8m

Mar 31 2018CA$273kCA$273k

-CA$7m

Compensation vs Market: Dan's total compensation ($USD576.21K) is above average for companies of similar size in the Canadian market ($USD176.04K).

Compensation vs Earnings: Dan's compensation has increased whilst the company is unprofitable.


CEO

Dan Legault (65 yo)

15yrs

Tenure

CA$784,861

Compensation

Mr. Daniel Marcel Legault, also known as Dan, J.D., L.L.B, served as the Independent Chairman at Klinik Health Ventures Corp. and served as its Independent Director since April 17, 2019 and served as its P...


Leadership Team

NamePositionTenureCompensationOwnership
Daniel Legault
President15yrsCA$784.86k2.13%
CA$ 333.2k
Alain Wilson
Chief Financial Officer8.4yrsCA$219.93k0.13%
CA$ 20.3k
Scott Curtis
Chief Operating Officer1.8yrsCA$316.21k0.22%
CA$ 33.9k
David Vaughan
Chief Development Officerno dataCA$423.61k0.050%
CA$ 7.9k
Joseph Stauffer
Chief Medical Officer4.1yrsCA$1.13m0.48%
CA$ 75.2k
Ana Stegic
Executive Director of Clinical Operations3yrsCA$263.34k0.079%
CA$ 12.3k
Christina Cameron
Vice President of Investor Relationsno datano datano data
Philip Stern
Vice President of Communicationsno datano datano data

4.1yrs

Average Tenure

65yo

Average Age

Experienced Management: ATE's management team is considered experienced (4.1 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/28 23:18
End of Day Share Price 2024/04/08 00:00
Earnings2023/12/31
Annual Earnings2023/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Antibe Therapeutics Inc. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sally YanchusBrookline Capital Markets
Tania Armstrong-WhitworthCanaccord Genuity
Robert GoffEchelon Wealth Partners Inc.